Advanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration Trials

  Advanced Cell Technology Announces Interim Data from Its Three Ongoing
  Macular Degeneration Trials

Company To Discuss Data as Part of Third Quarter Financial Results on Today’s
                               Conference Call

Business Wire

MARLBOROUGH, Mass. -- November 08, 2012

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of
regenerative medicine, announced today that its upcoming conference call on
its third quarter financial results will also provide some representative
examples of data being collected from patients in its clinical trials for
forms of macular degeneration. The Company has treated 13 patients thus far in
its three ongoing trials for dry age-related macular degeneration (dry AMD)
and Stargardt’s Disease (SMD) using human embryonic stem cell (hESC)-derived
retinal pigment epithelial cells. The first two trials were initiated in July
of 2011. The three clinical trials involve four of the top-ranked eye
hospitals in the U.S., and two of the leading eye hospitals in the U.K.

Across the various clinical trial sites, with regular patient follow-up, no
adverse safety issues relating to the transplanted cells have been observed.
At up to 16 months following treatment, no hyperproliferation, tumorigenicity,
ectopic tissue formation, or apparent rejection were observed in any of the 13
patients at any time. Detailed clinical and diagnostic laboratory assessments
were performed at multiple post-transplantation evaluations. In addition to
monitoring the safety of the transplanted cells, the clinicians have also been
carefully assessing patients – on regular follow-up visits – for evidence of
anatomical and functional integration of the RPE cells. The RPE layer plays a
central role in the health and function of the photoreceptor layer. In
treating various forms of macular degeneration, such as dry AMD and SMD, the
goal of the company’s RPE cell therapy is for repair and replacement of those
areas in the eye where the RPE layer has degraded with new cells, and in doing
so, recapitulate the correct working environment around the photoreceptor
layer. At a recent meeting of the various U.S. and U.K. surgeons leading the
clinical trials, the Company and surgeons reviewed the data from various
patients and discussed next steps and strategies for the existing trials and
designs for future phase II and III studies.

“Using high resolution imaging technology, we have been observing evidence
indicating that the transplanted RPE cells are getting to the right place in
the sub-retinal space, engrafting and are apparently resurfacing areas of the
retina with a new RPE layer,” said Robert Lanza, M.D., ACT’s chief scientific
officer. “With multiple follow-ups happening across multiple trial sites with
these patients, we also continue to see an encouraging trend with respect to
subjective and objective observations relating to visual acuity, color
perceptions and contrast in vision. In the case of the first dry AMD and SMD
patients, the visual acuity gains we saw more than a year ago continue to
persist.”

The RPE layer plays a central role in the health and function of the
photoreceptor layer. In treating various forms of macular degeneration, such
as dry AMD and SMD, the goal of the company’s RPE cell therapy is for repair
and replacement of those areas in the eye where the RPE layer has degraded
with new cells, and in doing so, recapitulate the correct working environment
around the photoreceptor layer.

Gary Rabin, chairman and CEO, in reference to the conference call scheduled
for 4:30 p.m. EST today, said, “We are extremely pleased with these results,
and plan to visually share a few examples today. While we remain cautious as
the data is still very preliminary, the enthusiasm it has created within our
clinical group makes me believe that we are ready to focus on earlier stage
dry AMD and SMD patients where we hope we to show that our RPE therapy may be
a meaningful treatment for these debilitating, sight-threatening diseases,
while addressing a large unmet medical need.”

With respect to the conference call, interested parties may dial (888)
264-3177 or (706)902-4345 using reference conference ID number 90962762. The
call will be available live and for replay by webcast at:
http://us.meeting-stream.com/advancedcelltechnology110812.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292